<DOC>
	<DOC>NCT02924064</DOC>
	<brief_summary>This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with metformin.</brief_summary>
	<brief_title>Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>A signed and dated informed consent form obtained from the subject, in accordance. The subject is aged ≥18 years at signature of the informed consent form. Hospitalization status: outpatient. The subject has a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit (Day 28). The subject's type 2 diabetes mellitus is managed by metformin monotherapy ≥1000 mg/day plus diet and exercise therapy, and the dosage or dose regimen of metformin and diet and exercise regimen has not been changed for at least 8 consecutive weeks at the screening visit (Day 28). Subjects who cannot do exercise due to complication are not limited to this criteria. The subject's HbA1c is ≥ 7.0% and &lt; 10.0% at the screening visit (Day 28) and on Day 14. The subject has a history of type 1 diabetes mellitus or a secondary form of diabetes. The subject has received insulin within 1 year prior to the screening visit (Day 28), with the exception of insulin therapy during hospitalization or insulin therapy for medical conditions not requiring hospitalization (&lt; 2 weeks' duration). The subject has received an antidiabetic drug within 8 weeks prior to the screening visit (Day 28).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>